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In April 2020 the results of the ISCHEMIA trial 
were finally fully published [1]. Few trials have trig-
gered such a level of controversy and dispute among 
cardiologists and cardiac surgeons since its oral pres-
entation at American Heart Association Congress 
2019. Some colleagues have heralded the study as 
the terminator of elective percutaneous coronary 
intervention (PCI) in patients with chronic coronary 
syndrome (CCS), while others have speculated about 
the negligible role left for functional testing, which 
could be relegated to practical irrelevance after the 
trial consecrated coronary computed tomography 
angiography (CCTA) as the gate-keeper of diagnostic 
workflow, a trend already consolidated in the latest 
iteration of the guidelines of the European Society 
of Cardiology [2]. The prompt reaction came as no 
surprise from all challenged sectors: interventional 
cardiologists offered their own interpretation of the 
results, of course diametrically opposed to the one 
endorsed by their conservative nemesis. Likewise, 
non-invasive cardiologists articulated the defence 
of functional tests, advocating their clinical and 
logistic advantages to counterbalance the threat of 
the unrelenting CCTA. Symposia and social media 
have provided a platform for passionate discussions 
about the future of cardiology after ISCHEMIA, but 
the bloodiest combats are by far those related to the 
indications of PCI in patients with CCS.
Why is this happening? Niccolò Machiavelli ad-
vised the young Lorenzo de’ Medici to be merciless 
in punishing the rebellion of his rivals, but always 
respecting their properties, because “Men sooner 
forget the death of their father than the loss of their 
patrimony” (Il principe) [3]. ISCHEMIA is directly 
threatening the patrimony (i.e., the modus vivendi, 
the areas of expertise, the source of prestige) of 
many heart specialists, who now feel compelled 
to defend it at any cost. Add to this, the classical 
rivalry between conservative and interventional 
cardiologists, fed with envy and resentment re-
garding the uneven distribution of resources, the 
mean attitude of the clinical gatekeeper, the ar-
rogant demeanour of interventional colleagues in 
the discussion of a patient’s therapy, etc. (multiple 
arguments brandished worldwide, even in the most 
balanced cardiovascular institutes, for years) and 
the explosive cocktail will be served. For those 
resentful of interventional cardiologists and 
heart surgeons, the least excuse to bash their 
rivals will always be welcomed; whilst for pas-
sionate interventional cardiologists, no study 
is ever going to dissuade them from stent-
ing. Each one’s prejudices will ever prevail, 
regardless of the evidence. Let us now make 
a balanced, scientific, neutral and critical review of 
the facts from ISCHEMIA, so we can glimpse the 
truth and better understand the optimal therapeutic 
options for patients with CCS. As authors a com-
mon disclosure is interventional cardiology, but 
we all share an aspiration for patient-focused care, 
delivered by a comprehensive team approach, as 
evidenced by our respective career paths.
Summary of the trial
The ISCHEMIA trial randomized 5179 patients 
with moderate or severe ischemia on functional 
testing to an initial invasive (coronary angiography 
and eventual revascularization) vs. an initial con-
servative strategy (optimal medical therapy alone): 
n = 2588 and 2591, respectively. Myocardial is-
chemia was proven in 75.5% with stress imaging 
methods (49.6% nuclear, 20.9% echo, 5.0% cardiac 
magnetic resonance) and in 24.5% with an exercise 
tolerance test. Following confirmation of ischemia, 
CCTA was performed to rule out left main (LM) 
stenosis or non-obstructive coronary artery dis-
ease (CAD) [4, 5]. After a median follow-up of 3.2 
years, there was no significant difference in the 
primary endpoint, a composite of cardiac death, 
non-fatal myocardial infarction (MI) and hospitali-
zation for unstable angina, heart failure or resusci-
tated cardiac arrest [1]. Contrary to many other 
trials, the need for revascularization was left 
out of the primary outcome, as the trial tested 
the initial strategy, rather than clinical benefit 
of revascularization itself. Within the conserva-
tive arm, 26% of patients eventually underwent 
coronary angiography (“cross-over”), 21% revascu-
larization and 15% were revascularized before the 
occurrence of an event. Furthermore, 26% of the 
revascularizations in the invasive arm were surgi-
cally performed. These results were interpreted as 
no clear advantage of an early invasive strategy for 
the reduction of major clinical endpoints in patients 
with CCS. Nonetheless, the invasive arm reported 
significantly better quality of life (QoL) than the 
conservative arm, particularly in patients who were 
symptomatic at the time of randomization, results 
not replicated in asymptomatic patients [6].
…and the winner is…
Clinical trials risk being interpreted in the same 
way as a soccer match: one arm wins or the match 
results in a tie. This is a risky oversimplification 
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of such a precious collection of data, disregarding 
lots of meaningful information extending beyond 
a mere p-value [7]. However, it is unavoidable, as 
cardiologists do not usually have the time or the 
capacity to “deep dive” into every scientific report, 
particularly on topics far from their areas of exper-
tise. Therefore, a simple ‘soccer-style’ report is 
likely to provide a take-home-message. Thousands 
of examples can be found concerning the ISCHEMIA 
trial on social media: invasive strategy won, invasive 
strategy lost, etc. For those who bet for one strategy, 
ISCHEMIA has calculated their error likelihood: 
those arguing against the invasive strategy have 
a 24.5% probability of being wrong, while those argu-
ing against the conservative strategy have a 0.1% 
probability of being wrong (results of the Bayesian 
analysis) [1].
Although the authors conclude that there is 
no significant difference between the strategies, 
the data deserve careful attention.
1. The conclusion cannot be applied to important 
groups of patients excluded from the trial:
 — CCS and LM stenosis;
 — CCS with no proof of myocardial ischemia;
 — CCS with very severe ischemia (e.g. fall 
in blood pressure, very limited functional 
capacity) were not likely enrolled by sites;
 — CCS with an unacceptable degree of an-
gina;
 — CCS and left ventricular ejection fraction 
< 35%;
 — CCS and heart failure New York Heart 
Association (NYHA) III/IV;
 — CCS and valvular disease.
2. Periprocedural MI had a heavy weight on 
the final results, however no data have been 
presented so far differentiating periprocedural 
MI between PCI and coronary bypass surgery.
3. The study was burdened with slow recruit-
ment and a lower-than-expected incidence of 
events. When this happens, the suspicion of 
possible selection bias always overshadows 
the results. In fact, the initial sample size cal-
culated that 8000 patients would be required 
to reach the primary endpoint, but had to be 
reduced to the final 5179 due to difficulties 
with enrolment.
4. Furthermore, a number of critical variables 
were unevenly distributed between the groups, 
in favour of less risk within the conservative 
arm. The invasive arm had numerically more 
heart failure (4.3% vs. 3.6%, p = 0.207), stroke 
(3.2% vs. 2.6%, p = 0.219), cerebrovascular 
disease (7.8% vs. 6.8%, p = 0.194), peripheral 
artery disease (4.5% vs. 3.4%, p = 0.049) 
and were more symptomatic (daily or weekly 
angina at randomization 21.7% vs. 18.9%, 
p = 0.049). Of note, the difference in the last 
two variables was statistically significant. Al-
though this may happen by chance, even after 
perfect randomization, this observation raises 
suspicion of selection/allocation bias and has 
a potential impact on the outcome, disadvan-
taging the invasive arm.
5. The most powerful argument is however the 
evolution of the event-curves. For the pri-
mary outcome it seems clear that the initial 
invasive strategy pays a higher price 
early, mainly at the expense of a higher 
incidence of periprocedural MI, but then 
the invasive management confers an 
advantage for the event-free survivors 
over those treated with a conservative 
strategy. The slope of the curve flattens in the 
invasive arm compared with the conservative 
arm, and the curves intersect at approximately 
2 years of follow-up. With continued diver-
gence to the 4th year of follow-up when 
the differences in the primary outcome 
become statistically significant: 13.3% 
vs. 15.5% in the invasive and conserva-
tive arms, respectively. However, the final 
report is non-significant. How is this possible? 
From a statistical point of view there are just 
two possibilities: 1) either the trends in the 
curves change after the 4th year or 2) the 
sample size gets considerably reduced, thus 
becoming underpowered to prove statistical 
significance. Looking at the chart, the curves 
seem to run parallel, but the number at risk re-
duces from 1463 at 4 years to just 564 at 5 years 
(a reduction by almost two thirds). This cannot 
be justified by the number of events. Therefore, 
the second option (reduction of the sample 
size) seems the most plausible explanation for 
the final lack of statistical significance. Keep 
in mind that the primary endpoint is reported 
as Cox regression, that takes into account the 
whole-time range, and the median follow-up is 
3.2 years (the study was initially planned for 
4 years). Therefore, the primary endpoint in 
ISCHEMIA reports just a Kaplan-Meier esti-
mate, instead of a truncated follow-up, even 
for all patients. Actually, in the appendix the 
hazard rates of all endpoints continue diverging 
in favour of the invasive strategy [1]. This con-
firms that more patients need follow-up for 
a longer time to report a statistically sig-
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nificant difference in favour of the invasive 
strategy. The authors calculated the Bayesian 
likelihood to reach this statistically significant 
difference, maybe to justify the publication 
at this point, but still the interventional com-
munity will be looking forward to the results 
following additional follow-up.
 The same phenomenon is observed with 
other hard composite endpoints (cardiovascular 
death + non-fatal MI; non-fatal MI alone): initially 
a higher incidence in the invasive arm (due to 
more peri-procedural MI), followed by a flatter 
slope than the conservative arm; intersection 
of the curves at 2 years and statistically sig-
nificant difference at 4 years. To be precise, 
non-fatal MI shows the same trend, but it does 
not reach statistical significance as a separate 
variable. However, the incidence of non-
-procedural MI is significantly higher in 
the conservative arm (information available 
in the supplements). This is in line with results 
of preceding trials on the topic [8].
In summary, it can be argued whether there is 
a winner, but it is obvious that an invasive strategy 
is effective.
Concern in the departments  
of dermatology worldwide
Those who have strongly advocated for the cur-
tailment of interventional labs for patients with CCS 
in the post-ISCHEMIA era, must also keep in mind 
the superior QoL of the initial invasive strategy 
in symptomatic patients [6]. Many interventions 
and medical therapies aim to improve QoL, rather 
than to reduce major cardiovascular endpoints. This 
might seem a modest goal, but, for example, the 
revascularization of chronic total occlusions is justi-
fied by the clear improvement in QoL [9], while the 
benefit in hard endpoints is debatable [7, 10]. Actu-
ally, some medical specialties, like dermatology, are 
almost fully dedicated to the relief of symptoms and 
the improvement of QoL. Should they worry about 
the results of ISCHEMIA? Following the rationale 
of some PCI-haters, the closure of cathlabs post- 
-ISCHEMIA, as a consequence of an unclear reduc-
tion in major cardiovascular events, should be mir-
rored by the restriction of activity of dermatologists 
to their oncological interventions and the treatment of 
pemphigus. After an informal survey, dermatologists 
do not seem concerned at all, maybe because they 
have not forgotten that their duty as physicians 
is also relieving symptoms and improving the 
quality of life of their patients.
Back to anatomy in times of physiology
The scenario depicted by some colleagues for 
CAD after the ISCHEMIA trial elicits some con-
cerns about the role left for physiology. ISCHEMIA 
used CCTA as gate-keeper, to rule out LM steno-
sis or non-obstructive CAD. If it is accepted that 
neither the management strategy nor the level of 
ischemia in functional tests make any difference on 
the outcome, then the role left for functional tests 
would be negligible. Consequently, we would rely on 
a purely anatomical assessment, an approach whose 
limitations have been extensively documented pre-
viously [11, 12]. ISCHEMIA attempted to incorpo-
rate intracoronary physiology into the decision tree 
within the invasive arm, however, the methodology 
and realities of investigation were far removed from 
the evidence-base and current guideline recom-
mendations [13]. This might partially explain the 
differences in outcome between the ISCHEMIA 
trial and other physiology-guided trials in patients 
with CCS [14]. The interventionists’ willingness 
to ‘react’ to the angiographic anatomy in the light 
of non-invasive ischemia testing could often result 
in a suboptimal or even inappropriate interven-
tional approach, at odds with the findings achieved 
through physiology-guidance, which undoubtedly 
remains the invasive gold standard to optimize 
clinical outcomes [14]. Conversely, apparently 
mild angiographic lesions may have functional 
significance [15]. These cases may have been 
denied revascularization in this trial based on 
the results of computed tomography and angio-
graphy [15]. This is a clear step backward. We 
are still learning about the limitations of anatomy 
to guide the decision-making in CCS. Stenosis 
is only one factor contributing to the functional 
relevance of the lesion and many other epicardial 
and microcirculatory factors must be considered 
[16]. The beauty of physiology is integrating all 
these factors to give the operator meaningful 
directions to take the best therapeutic decision. 
Interventional cardiology is constantly evolving 
and must continue progressing in the direction 
of physiology-guidance. This is in line with the 
growing interest in research funding programs for 
precision medicine. The era of personalized medi-
cine and precision-PCI must not be derailed by 
a return to an ‘out-dated’ anatomical assessment 
and a uniform “prêt-à-porter” strategy. Patients as 
individuals should be granted individual answers 
to their medical problems. Interventional cardio-
logy must continue moving toward personalized 
medicine and away from a “one-size-fits-all” 
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strategy. The debate is indeed quite old. The 
COURAGE trial already challenged the role of PCI 
for CCS [17] in 2007. However, the FAME trials 
definitively proved the benefit of PCI in CCS, if 
performed under physiology guidance [12, 14]. In 
the ISCHEMIA trial, 20.3% of interventions were 
physiology-guided, and although exceeding the 
average global usage in routine clinical practice 
[18], this falls below current recommendations 
[13, 19].
Attention to the subgroup analysis
A careful analysis of the subgroups is also very 
educational [20]. Let us remember that subgroup 
analyses do not necessarily require a statistically 
significant value. They rather intend to detect trends 
in order to better understand the results or to gener-
ate hypotheses that can be properly tested in future 
studies. Firstly, subgroup analysis suggests that 
the degree of ischemia does play a role. The more 
ischemia, the greater the advantage of an invasive 
strategy. This trend is consistently observed in the 
results stratified by degree of baseline ischemia, 
number of diseased vessels and involvement of 
the proximal left anterior descending artery. This 
observation eases the interpretation of the results 
from a pathophysiological point of view. The study 
actually ruled out LM disease, the lesion with 
greatest ischemic burden and most myocardium at 
jeopardy, because it was deemed unethical to deny 
revascularization to those patients.
However, it is puzzling to observe that patients 
with new-onset or worsening angina over the preced-
ing 3 months benefit less from an invasive strategy 
than the subgroup with a stable profile. This observa-
tion highlights the difficulty in obtaining an accurate 
assessment of symptoms. A patients’ perception of 
their own disease is extremely variable, combined 
with significant variability in a physicians’ interpreta-
tion of symptoms, thus challenging the reproducibility 
of results. All medical schools worldwide emphasise 
the importance of clinical anamnesis, because other-
wise students and future doctors would tend to rely on 
diagnostic tests instead of talking to the patient, who 
must always remain the main focus. The anamnesis 
is critical to humanise medicine, to preserve its most 
intimate essence, but it is too inaccurate in building 
solid scientific evidence.
Conclusions
In line with Socratic dialog, knowledge is ad-
vanced by a questioning approach: 1) Why did the 
investigators plan a covariate-adjusted Cox analysis? 
A randomized trial of that size would not need to 
adjust for any covariate. Which covariates were then 
introduced for the adjustment? 2) The statistical 
decision to use non-parametric tests in a trial with 
5179 patients was perhaps not so convincing for all 
the experts. 3) Why were 111 patients in the inva-
sive arm not revascularized because their anatomy 
was “not suitable for any kind of revascularisation”? 
This means 4.3% of the invasive group and 26.4% 
of the patients not revascularized in that group? 
Is this representative of current state-of-the-art? 
Etcetera. We would never finish. While we wait for 
further data of the curve separation to confirm our 
interpretation we should agree that the ISCHEMIA 
trial has given a clear signal of the beneficial effect 
of an early invasive strategy in patients with CCS: 
significant improvement in QoL and reduction of 
non-procedural MI, together with a trend to the 
reduction of cardiovascular mortality. However, 
the invasive management pays a price in terms of 
peri-procedural MIs, thus the comparison starts at 
a disadvantage. At 2 years the curves cross-over 
and at 4 years the difference is statistically signifi-
cant in favour of an invasive strategy. However, the 
Cox analysis does not reach statistical significance 
because the number at risk is dramatically reduced 
(by two-thirds) after 4 years. More patients or 
a longer follow-up would be required to prove the 
superiority of an invasive strategy.
Conversely, the advantage of an invasive strat-
egy is less than the interventional cardiologists 
used to think, so an initial conservative approach 
might be a reasonable alternative in selected 
patients [21]. Likewise, the benefit of revascu-
larization in asymptomatic patients is unclear and 
difficult to justify after ISCHEMIA for prognostic 
reasons. All these questions will require specific 
answers in the future, always keeping in mind that 
coronary interventions are moving toward physio-
logy guidance and precision medicine [22], rather 
than relying on the haziness of symptoms and the 
misleading nature of anatomy.
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